Low-dose radiation to trigger whole-body cancer effects
Part of Cancer clinical trials.
This trial tests whether giving a low dose of radiation to one spot can help shrink cancer in other, untreated areas (the “abscopal effect”) in people with multiple metastases. It may help by boosting the body’s response to stereotactic body radiotherapy (focused high-dose radiation) for tumors outside the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 19 or older) and can sign consent
- You have solid cancer proven by a biopsy, and it has spread outside the brain
- Your cancer treatment plan includes stereotactic body radiotherapy in 3 sessions for extracranial metastases
- There is at least one measurable tumor outside the brain that is not suitable for SBRT or palliative radiation, and that could be treated with low-dose radiation (bone metastases are not used for low-dose radiation)
- Your overall condition is fairly able to function (ECOG 0 to 2) and your blood counts are high enough for radiation
- You likely have at least 6 months to live, based on the study doctor’s judgment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how targeted radiation (SBRT) affects cancer biology and immune cells in people with colon cancer that has spread only to a small number of lung nodules. Your tumor tissue will be analyzed to see what changes after treatment.
This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.
This trial studies giving targeted high-dose radiation (SBRT) to liver metastases from colorectal cancer after initial treatment, with the goal of improving long-term control or cure. It may help people who have a limited number of liver spots that doctors think can be treated safely and effectively.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This trial tests how a single, high-dose radiation treatment (called SBRT) affects quality of life and outcomes for people with certain lung tumors. It's for adults with early-stage non-small cell lung cancer or a lung tumor that has spread from another cancer, as long as the tumor is small and in the outer part of the lung.
This trial studies stereotactic body radiation therapy (high-precision radiation given in a few sessions) for liver metastases when surgery isn’t possible. It may help shrink or control tumors in the liver and delay progression in people whose cancer has not spread outside the liver (or only to areas treated with a curative plan).
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.